Phase I/IIa Study for PM1032 in the Treatment of Patients With Advanced Solid Tumors
The study is being conducted to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of PM1032 for patients with advanced tumors, also to explore the recommended Phase Ⅱ Dose（RP2D） of PM1032.
Advanced Tumor
DRUG: PM1032 injection
Dose Limited Toxicity（DLT）, Occurrence of DLT after receiving PM1032 injection, up to 21 days|Assess the incidence and severity of treatment-related adverse events, The incidence and severity of treatment-emergent adverse events (TEAEs) and treatment related adverse events (TRAEs) graded according to NCI-CTCAE v5.0, Up to 30 days after last treatment
PM1032 is a Bispecific Antibody Targeting CLDN18.2 and 4-1BB.